Study of Insulin Lispro in Participants With Inadequately Controlled Type 2 Diabetes
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1117 participants.
Also called NCT01215955
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 1,117 participants
- Sponsor
- Registry
-
NCT01215955
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Austria, Brazil, Canada, Croatia, Denmark, France, Lithuania, Mexico, Poland, Puerto Rico, Romania, Russia, South Africa
- Registry status
- Completed
Technical summary
Registry record NCT01215955. Randomized; no masking; primary purpose treatment. Start 2010-12 (registry gives no type); primary completion 2013-01 (actual). Results posted on 2014-02-27.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of Insulin Lispro in Participants With Inadequately Controlled Type 2 Diabetes
- Acronym
- AUTONOMY
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Insulin lispro
- Intervention (Drug)
- Glargine
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct01215955- Content hash
6331be4891c1469d6a81731d3295c69e3a32e5b4a6d2531fc18bbc3cb995b5f0